About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Open for Trade Show & Conference Taking Place May 12–15 in Rosemont, IL ROSEMONT, IL, DECEMBER 18, 2024 – Registration is now open for the 2025 Food Safety Summit education program, ...

The latest revisions to the Evaluation of Corporate Compliance Programs (ECCP) guidance show the Department of Justice (DOJ) is wary about ...

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy ...

Putting Protection and Resilience at Center Stage - 08:10 Cybersecurity is a remarkably dynamic industry. New trends, ...

After a median follow-up of 9.6 years, irradiated patients had a 10-year overall survival (OS) of 81.4% versus 82% for those ...

Investors are deciphering both new and old variables to identify opportunities in 2025, while being wary of risks from the ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

"We've overindexed on problem articulation, to the point of problem admiring. The risk is that we are analyzing ourselves ...

The U.S. Department of Defense released the final regulations for its Cybersecurity Maturity Model Certification (CMMC) ...

AI and GenAI are redefining cybersecurity strategies, from Zero Trust to predictive analytics. Explore key takeaways from the ...